Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Two Australian states on COVID-19 alert after infected woman's interstate travel

06/09/2021 | 09:51pm EDT

* Queensland cases pose low community risk

* NSW, Queensland lists virus hotspots

* Victoria logs 4 cases, easing of restrictions to proceed

* Second AstraZeneca blood-clot death reported

SYDNEY, June 10 (Reuters) - Two Australian states are on COVID-19 alert after an infected woman and her husband travelled from Victoria, the epicentre of country's latest outbreak, through the states of New South Wales and into Queensland, visiting dozens of sites enroute.

Authorities in New South Wales and Queensland are rushing to trace close contacts and locate virus hotspots. The couple may face criminal charges for breaching COVID-19 border restrictions.

The 44-year-old woman tested positive for COVID-19 once in Queensland, authorities said late on Wednesday, and her husband has since tested positive.

Queensland state Health Minister Yvette D'Ath told reporters in Brisbane on Thursday that the couple's tests suggested they were likely at the end of their infectious period.

"This means the risk is lower than we were expecting yesterday, which is really positive news," D'Ath said. No other cases were reported from the state.

Australia has largely contained all prior outbreaks through snap lockdowns, regional border controls and swift contact tracing, with just over 30,200 cases and 910 deaths since the pandemic began. It has reported zero cases most days this year.

Queensland has issued alerts for parts of Sunshine Coast, a popular tourist spot, and two regional areas.

NSW authorities said the pair travelled mostly through regional towns over five days last week.

"The message broadly to our regional communities is be on high alert, this is a real and present danger to us, having people who are positive, traveling through our state stopping at multiple venues puts our state at risk," NSW state Health Minister Brad Hazzard said.

NSW, the country's most populous state, has not reported any locally acquired cases of COVID-19 in more than a month, while Queensland last reported cases in late March.

Australia on Thursday also reported a 52-year-old woman died from serious blood clots with a low blood platelet count after having the AstraZeneca vaccine, the second death in Australia linked to the vaccine out of 3.6 million doses given.

"We are getting very good at diagnosing and treating this particular event. But in this particular case that was not successful," Chief Medical Officer Paul Kelly told reporters.

The country has now had a total 35 confirmed and 13 probable cases of the rare side effect. The AstraZeneca vaccine is recommended only for people over 50 in Australia.

The government on Thursday extended a ban on cruise ships entering Australia to Sept. 17. The curb has been in place since March 2020, when cruise ships were the source of most of Australia's early COVID-19 cases.


On Thursday, Victoria reported four new locally acquired cases, versus one case a day earlier, taking the total infections in the latest outbreak to 90.

The new cases, all from the same household, come as Melbourne prepares to come out of a two-week lockdown on Thursday night, although some curbs on travel and gatherings remain.

Melbourne's five million residents must stay within 25 kms (15 miles) of their homes, a move that could inflict more pain on businesses in rural areas as officials seek to limit community transmission during an upcoming long weekend.

Though Thursday's cases are not linked to any other clusters in the latest outbreak, the lifting of lockdown in Melbourne will proceed due to low-risk levels, Victoria state Acting Premier James Merlino said during a televised media conference.

Separately, New Zealand authorities have moved three Melbourne residents into managed isolation after they boarded their flight from Sydney to beat a travel ban imposed in response to the Victoria outbreak, New Zealand media reported.

New Zealand began quarantine-free travel for Australian travellers in April, a pandemic milestone, but paused the so-called "travel bubble" with Victoria late last month. (Reporting by Renju Jose; Additional reporting by Sonali Paul; Editing by Jacqueline Wong and Michael Perry)

© Reuters 2021
All news about ASTRAZENECA PLC
04:22pTHE LATEST : Israel delays reopening of borders to tourists
10:39aGENPREX  : to Move Forward With Phase 1/2 Trial of Lung Cancer Combo Therapy
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
09:25aSTREET COLOR : Two US House Panels Seeking Details on Emergent Relationship Betw..
08:57aGenprex Shares Rise 8% on FDA Review of Reqorsa Trial
06:49aASTRAZENECA  : First-in-class approval in China in this setting and first regula..
04:17aASTRAZENECA  : Receives Conditional Approval in China for Lung Cancer Treatment
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
02:05aASTRAZENECA  : Orpathys approved in China for patients with lung cancer and MET ..
01:39aASTRAZENECA  : What you need to know about the coronavirus right now
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,7x
Yield 2021 2,45%
Capitalization 152 B 153 B -
EV / Sales 2021 5,26x
EV / Sales 2022 4,54x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 116,46 $
Average target price 132,57 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.01%152 574
JOHNSON & JOHNSON3.96%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.7.61%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.7.05%202 586